Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of multiple myeloma
Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of multiple myeloma. Blood 102 (2003) 3447-3454
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib
Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101 (2004) 8120-8125
NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS1145
Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., and Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS1145. Blood 107 (2006) 827-834
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation
Bruno B., Patriarca F., Sorasio R., et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 91 (2006) 837-839
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
van de Donk N.W., Kroger N., Hegenbart U., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 107 (2006) 3415-3416